Why Hospital Consumable Markups Face Regulatory Scrutiny
Recent audits across institutional pharmacies have intensified the regulatory debate surrounding medical device pricing in India. Consequently, industry leaders are urging authorities to establish pragmatic trade margin frameworks. The Association of Indian Medical Devices Industry (AiMeD) highlighted that consumables warrant equal regulatory scrutiny alongside pharmaceuticals.
Hospital Pharmacy Audits Uncover Inflated Margins
State inspections in Uttar Pradesh recently examined 214 pharmacies attached to private hospitals and medical colleges. Specifically, these audits exposed discrepancies reaching up to 67 times between procurement costs and retail prices. For instance, pharmacies purchased a Polymyxin-B injection for ₹74.09 but printed an MRP of ₹4,980.94. Furthermore, common clinical consumables revealed equally dramatic markups. Investigators documented three-way stop cocks purchased for ₹6.40 carrying an MRP of ₹163. As a result, patients face inflated out-of-pocket expenses during inpatient admissions, a challenge often managed by professionals trained through a certification course in general practice.
AiMeD Advocates Rational Medical Device Pricing
Following earlier scrutiny in Maharashtra and Karnataka, regulatory attention has shifted northward. However, industry representatives emphasise that distorted trade margins represent a nationwide challenge. Therefore, AiMeD has proposed a structured approach to medical device pricing rather than arbitrary caps. The association recommends capping markups between two to six times the landed or factory price. In addition, consumables priced under ₹1,000 should carry a maximum markup of four times. This structured formula protects healthcare consumers without crippling commercial distribution networks.
Supply Chain Risks and the Need for Pilot Testing
Healthcare leaders caution that overly aggressive price controls can trigger severe unintended consequences. During the pandemic, several states enforced drastic price ceilings based on public procurement tender values. Consequently, manufacturers faced disrupted logistics and localized device shortages. Distributors could not maintain adequate inventory across remote healthcare facilities. Thus, AiMeD advocates implementing phased national pilots before enacting statutory nationwide mandates. A uniform policy ensures fair retail pricing while sustaining domestic manufacturing resilience across India.
Frequently Asked Questions
Q1: Why are regulatory authorities scrutinising hospital pharmacy markups?
State audits revealed excessive margins between purchase rates and maximum retail prices, which heavily inflate patient bills.
Q2: What markup cap does AiMeD recommend for medical consumables?
The industry body recommends a markup band of two to six times, with a four-fold cap for items under ₹1,000.
Q3: Why does industry caution against excessive price capping?
Moreover, overly restrictive caps during past crises caused severe product shortages by failing to cover essential distribution and storage expenses.
References
- Medical devices body pushes for rationalised trade markups amid rising scrutiny - ETHealthworld
- Trade Margin Rationalisation: Spotlight On UP - Medgate Today
- MedTech sector backs Mundhe's push for trade margin rationalisation - ETHealthworld
